New drug trial aims to unleash immune system against skin cancer
NCT ID NCT03161431
Summary
This early-stage study is testing a new oral drug called SX-682 in people with advanced melanoma that has spread. The goal is to see if SX-682 can safely block certain cells that shield the tumor, allowing the patient's own immune system, boosted by an existing immunotherapy drug, to better attack the cancer. Participants will take SX-682 alone for 21 days, then in combination with pembrolizumab for up to two years.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MELANOMA STAGE III are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Dana-Farber Cancer Institute
Boston, Massachusetts, 02215, United States
-
MD Anderson
Houston, Texas, 77030, United States
-
Massachusetts General Hospital Cancer Center
Boston, Massachusetts, 02114, United States
-
Mayo Clinic
Rochester, Minnesota, 55905, United States
-
University of Miami
Miami, Florida, 33136, United States
-
Wilmot Cancer Institute - University of Rochester
Rochester, New York, 14642, United States
Conditions
Explore the condition pages connected to this study.